Results 171 to 180 of about 81,076 (308)

Efficacy of Upadacitinib in a Middle‐Aged Man With Netherton Syndrome Refractory to Dupilumab: A Case Report

The Journal of Dermatology, EarlyView.
Bo‐Jie Yu, Pei‐Ling Li, Bing‐Sian Lin, Shou‐En Wu, Chih‐Tsung Hung   +4 more
wiley   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Progression of mycosis fungoides in a patient receiving a Janus kinase inhibitor. [PDF]

JAAD Case Rep
Stankiewicz JM, Kersten JM, Merkus VA, de Haan S, Jansen PM, Vermeer MH, Ottevanger R.   +6 more
europepmc   +1 more source

FDA-approved small-molecule kinase inhibitors [PDF]

, 2015
Clausen, Mads Hartvig, Nielsen, Thomas E., Wu, Peng   +2 more
core   +1 more source

The relationship between the cannabinoids and cardiac remodelling: A comprehensive review of pivotal mechanisms and emerging evidence

British Journal of Pharmacology, EarlyView.
Cardiac remodelling and fibrosis after myocardial infarction or during chronic diseases, such as arterial and pulmonary hypertension or diabetes mellitus, continue to be the more important prognostic factors in determining survival, and so the search for effective anti‐fibrotic interventions is an important target for research and therapy in cardiology.
Anna Krzyżewska, Marta Baranowska‐Kuczko, Hanna Kozłowska   +2 more
wiley   +1 more source

Janus Kinase Inhibitor: A Possible Cause of Hyperammonemic Encephalopathy? [PDF]

J Clin Neurol
Park JH, Kim DH.
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Flagellate erythema-like persistent eruption of Still's disease treated with a Janus kinase inhibitor. [PDF]

JAAD Case Rep
Kassels A, Pham CT, Moon D, Lee BA, Rojek NW.   +4 more
europepmc   +1 more source

A gastrointestinal locally activating Janus kinase inhibitor to treat ulcerative colitis. [PDF]

J Biol Chem, 2023
Bu Y, Traore MDM, Zhang L, Wang L, Liu Z, Hu H, Wang M, Li C, Sun D.   +8 more
europepmc   +1 more source

Targeting Inflammation and Immune Regulation in Chronic Inflammation Associated Cancers

Cancer Science, EarlyView.
Chronic inflammation sustains activation of key inflammatory pathways, including Nuclear factor kappa B (NF‐κB), Interleukin‐6‐signal transducer and activator of transcription 3 (IL6‐STAT3), Phosphoinositide 3‐kinase/Akt (PI3K/Akt), and Wingless/β‐catenin (Wnt/β‐catenin) signaling. This promotes immune dysregulation through the expansion and functional
Lawan Rabiu, Mengzhu Chinn, Feng Chen, Yerkezhan Yerkinkazhina, Yuan Tian, Wei‐Guo Zhu   +5 more
wiley   +1 more source